Key Takeaways
- •The glucagon-like peptide 1 (GLP-1) receptor agonist market has become one of the most intensely watched segments in the pharmaceutical industry, driven by surging demand for diabetes and obesity treatments.
- •The 60% market share figure reflects Eli Lilly’s strong performance in the GLP-1 sector, which includes not only Mounjaro but also older products and newer entrants.
- •Market share estimates are typically derived from prescription data (e.g., IQVIA, Symphony Health) and financial filings.
Eli Lilly Secures 60% GLP-1 Market Share as Mounjaro Revenue Rises 125%
The glucagon-like peptide 1 (GLP-1) receptor agonist market has become one of the most intensely watched segments in the pharmaceutical industry, driven by surging demand for diabetes and obesity treatments. A recent analysis by 24/7 Wall St. highlights a clear shift in competitive dynamics: Eli Lilly now holds an estimated 60% market share within the GLP-1 category. This commanding position is fueled largely by the remarkable performance of Mounjaro (tirzepatide), whose revenue has jumped 125% in the latest reporting period. The data, sourced from the 24/7 Wall St. report and listed under Google News’s Novo Nordisk Lilly feed, underscores how Lilly has overtaken its chief rival Novo Nordisk in this high-stakes therapeutic arena.
Eli Lilly Captures 60% of the GLP-1 Market
The 60% market share figure reflects Eli Lilly’s strong performance in the GLP-1 sector, which includes not only Mounjaro but also older products and newer entrants. For context, GLP-1 receptor agonists were pioneered by Novo Nordisk with liraglutide (Victoza, Saxenda) and later semaglutide (Ozempic, Wegovy). For years, Novo Nordisk dominated the space, capturing the majority of prescriptions and revenue. However, the 24/7 Wall St. analysis reveals a dramatic reversal: Eli Lilly now controls roughly three-fifths of the market.
Market share estimates are typically derived from prescription data (e.g., IQVIA, Symphony Health) and financial filings. The 24/7 Wall St. report likely aggregates quarterly earnings reports, physician prescribing patterns, and pharmacy claims to arrive at the 60% figure. Such numbers are significant because they indicate not just revenue dominance but also patient adoption and clinician preference. The shift suggests that many patients and providers are choosing tirzepatide over semaglutide, a trend that has accelerated as Mounjaro’s indications expand.
Mounjaro’s 125% Revenue Surge
Mounjaro revenue has soared by 125%. This increase supports Eli Lilly’s market dominance. The 24/7 Wall St. piece notes this sharp rise. Such growth for Mounjaro contributes to the overall 60% share. Revenue figures underscore the product’s success. The report ties this directly to market capture.
To understand the magnitude, consider that Mounjaro was approved by the U.S. Food and Drug Administration in May 2022 for type 2 diabetes. By early 2024, it had already amassed billions in quarterly sales. The 125% revenue jump likely reflects several factors: expanded insurance coverage, increased manufacturing capacity, growing awareness among physicians, and the drug’s superior efficacy in clinical trials. In the SURPASS and SURMOUNT series of studies, tirzepatide demonstrated greater reductions in HbA1c and body weight compared with semaglutide. For example, in the SURPASS-2 trial, a 15 mg dose of tirzepatide led to a mean HbA1c reduction of 2.30% versus 1.86% for semaglutide 1 mg, while also producing more weight loss.
These clinical advantages have translated directly into commercial success. Lilly has also been aggressive in securing supply, investing billions in new manufacturing facilities. Meanwhile, Novo Nordisk has faced periodic shortages of Ozempic and Wegovy, creating an opening for Lilly to capture market share. The 125% revenue growth is not just a number; it represents millions of patients switching to or starting Mounjaro, as well as price increases (though net prices after rebates have been relatively stable in the U.S. market).
Scientific Context: How GLP-1 Drugs Work
The GLP-1 class mimics the action of the endogenous incretin hormone glucagon-like peptide 1. In the body, GLP-1 is released from intestinal L-cells after eating. It stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety in the brain. These actions lead to better blood sugar control and weight loss.
Mounjaro (tirzepatide) is unique because it is a dual agonist: it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is another incretin hormone that amplifies the effects of GLP-1. The dual mechanism is thought to produce additive or synergistic benefits. In the SURMOUNT-1 obesity trial, tirzepatide at the highest dose (15 mg weekly) led to an average weight loss of 22.5% after 72 weeks, compared with 2.0% for placebo. For many patients, that exceeds what is achievable with semaglutide alone.
The dual agonism also appears to improve metabolic parameters beyond glycemic control and weight loss, including blood pressure, lipid profiles, and liver fat content. Ongoing trials are exploring its use in non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction, and even chronic kidney disease. These potential expansions further solidify Lilly’s position in the GLP-1 market and beyond.
Market Implications and Competitive Landscape
Eli Lilly’s 60% hold in GLP-1 stands out. Mounjaro’s 125% revenue boost drives this. All information traces to the 24/7 Wall St. report.
The implications extend far beyond revenue numbers. Novo Nordisk, long the market leader, is now playing catch-up. The Danish company is investing in new formulations, including an oral semaglutide and a next-generation obesity drug, CagriSema (a combination of semaglutide and cagrilintide). However, manufacturing constraints have limited its ability to meet demand, and the recent removal of some strengths of Wegovy from shortage lists in the U.S. may not be enough to stem the tide.
Meanwhile, other competitors are entering the fray. Amgen, Pfizer, and a host of smaller biotechs have GLP-1 assets in development, some with novel mechanisms like oral peptides or dual/ triple agonists. But for now, the market is largely a two-player race, and Lilly has grabbed the inside track.
For biohackers and health-conscious readers, this market shift means greater access to highly effective weight loss and diabetes drugs, potentially at lower cost as competition intensifies. However, it also raises questions about long-term safety, cost to healthcare systems, and the ethics of using these drugs for cosmetic weight loss. The scientific community continues to study the real-world durability of weight loss, side effect profiles (nausea, vomiting, diarrhea, rare pancreatitis, and thyroid C-cell tumors in rodents), and the effects in non-diabetic populations.
Frequently Asked Questions
Q: What exactly is a GLP-1 receptor agonist, and how does tirzepatide differ from semaglutide?
A: GLP-1 receptor agonists are a class of drugs that mimic the incretin hormone GLP-1, which helps regulate blood sugar and appetite. Semaglutide (Ozempic, Wegovy) activates only the GLP-1 receptor. Tirzepatide (Mounjaro) activates both the GLP-1 receptor and the GIP receptor, a dual mechanism that in clinical trials has produced greater reductions in blood sugar and body weight compared with semaglutide.
Q: How is market share in the GLP-1 sector typically calculated?
A: Market share estimates are usually based on prescription volume data from organizations like IQVIA or Symphony Health, combined with quarterly revenue reported by manufacturers. The 24/7 Wall St. analysis likely used a combination of these sources to determine that Eli Lilly now holds about 60% of the GLP-1 market, driven by Mounjaro’s rapid uptake.
Q: Does the 125% revenue increase for Mounjaro include sales for both diabetes and obesity?
A: As of the most recent reporting period, Mounjaro is approved only for type 2 diabetes. However, many physicians prescribe it off-label for weight loss, and the drug is also available under the brand name Zepbound for obesity (approved in November 2023). The 125% revenue figure likely includes combined sales of both Mounjaro and Zepbound, as they are the same molecule. Lilly reports them separately in some filings but analysts often aggregate them.
Q: What are the main side effects and risks of tirzepatide?
A: The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal pain, which tend to diminish over time. More serious but rare risks include pancreatitis, gallbladder disease, hypoglycemia (especially when used with insulin or sulfonylureas), and thyroid C-cell tumors (observed in animal studies but not confirmed in humans). Patients with a personal or family history of medullary thyroid cancer should not take these drugs.